Loading stock data…
Nurix Therapeutics, Inc. (NRIX)
$23.38-0.36 (-1.52%)
Market ClosedLast close Jul 24
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nurix Therapeutics, Inc. in the Healthcare sector is trading at $23.38 with a market capitalization of $1.6B. Wall Street consensus targets $33.00 (16 analysts), implying a +41.1% move over the next 12 months. The stock is currently near its 52-week high of $25.09, remaining 39.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.04M↑ | $6.25M↓ | $13.58M↑ | $7.89M↓ | $44.06M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$94.20M↓ | -$92.50M↓ | -$83.09M↑ | -$91.39M↓ | -$48.32M |
| Net Income | -$89.53M↓ | -$87.17M↓ | -$78.22M↑ | -$86.42M↓ | -$43.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.40%
Volume
Today's trading volume
833,101
Recent News
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.
Company News for July 13, 2026
Companies In The Article Are:WDFC,DAL,NRIX and FCX
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -10.96% and -36.76%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.